What is molotinib (Ojjaara)?

Myelofibrosis, a rare cancer of the bone marrow, has attracted medical attention because it gradually damages the production of red blood cells. The root cause of this disease lies in the dysfunction of JAK signal transduction and transcription protein signal activator, resulting in patients with typical symptoms such as general discomfort, splenomegaly, and gradually worsening anemia. In recent years, an innovative drug called molotinib (Ojjaara) has emerged in the field of treating myelofibrosis. The main ingredient of molotinib is Momelotinib. This new drug was developed by the well-known pharmaceutical company GlaxoSmithKline (GSK) and brings new treatment hope to patients with myelofibrosis.

Molotinib is an inhibitor of wild-type Janus kinase 1 and 2 (JAK1/JAK2) and mutant JAK2V617F. These kinases play crucial roles in hematopoiesis and immune function. Compared with JAK3 and tyrosine kinase 2 (TYK2), this drug has a higher inhibitory effect on JAK2. Molotinib also inhibits activin A receptor type 1 (ACVR1), a property that helps increase iron availability and thereby promotes red blood cell production. After clinical trials, the drug has shown significant efficacy in treatment and its safety has been confirmed.

Molotinib is particularly suitable for the treatment of moderate or high-risk myelofibrosis, covering adult patients with primary or secondary anemia, such as myelofibrosis after polycythemia vera (PV) and after essential thrombocythemia (ET). This medication is usually given to patients in the form of oral tablets. The recommended dose is 200 mg once daily, with or without food.

However, patients need to be aware of several warnings and precautions when using molotinib, including an increased risk of infection, possible thrombocytopenia and neutropenia, hepatotoxicity, major adverse cardiovascular events (MACE), risk of thrombosis, and potential risk of malignancy. In addition, common adverse reactions include thrombocytopenia, bleeding, bacterial infection, fatigue, dizziness, diarrhea and nausea.

In general, molotinib (Ojjaara), as a new treatment drug, provides a new treatment approach for patients with myelofibrosis. When using it, patients should strictly follow the doctor's instructions and pay attention to the drug's indications, mechanism of action, and related usage precautions to ensure the effectiveness and safety of the treatment. Pay attention to the indications, mechanism of action, and related precautions for use to ensure the effectiveness and safety of the drug.